It is unclear whether patients on oral anticoagulants (OAC) undergoing a procedure using common femoral artery access have higher adverse events when compared to patients who are not anticoagulated at the time of the procedure. We retrospectively reviewed data from consecutive patients who underwent a cardiac procedure at a tertiary medical center. Patients were considered (group A) fully or partially anticoagulated if they had an international normalized ratio (INR) ≥1.6 on the day of the procedure or were on warfarin or new OAC within 48 h and 24 h of the procedure, respectively. The nonanticoagulated group (group B) had an INR <1.6 or had stopped their warfarin and new OAC >48 h and >24 h preprocedure, respectively. The index primary end point of the study was defined as the composite end point of major bleeding, vascular complications, or cardiovascular-related death during index hospitalization. The 30-day primary end point was defined as the occurrence of the index primary end point and up to 30 days postprocedure. A total of 779 patients were included in this study. Of these patients, 27 (3.5%) patients were in group A. The index primary end point was met in 11/779 (1.4%) patients. The 30-day primary composite end point was met in 18/779 (2.3%) patients. There was no difference in the primary end point at index between group A (1/27 3.7%) and group B (10/752 1.3%; =0.3155) and no difference in the 30-day primary composite end point between group A (2/27 7.4%) and group B (16/752 2.1%; =0.1313). Multivariable analysis showed that a low creatinine clearance (odds ratio OR =0.56; =0.0200) and underweight patients (<60 kg; OR =3.94; =0.0300) were independent predictors of the 30-day primary composite end point but not oral anticoagulation ( =0.1500). Patients on OAC did not have higher 30-day major adverse events than those who were not anticoagulated at index procedure.